

# MORPHOSYS AG

ISIN: DE0006632003 WKN: 663200 Asset Class: Stock

## Company

2024/07/08 11:26:39



Price  
**67.65**  
EUR

Difference ▲  
0.07%(0.05)



## Contact Details

MORPHOSYS AG Tel: +49-89-89927-0  
 -- Fax: +49-89-89927-222  
 Semmelweisstrasse 7 Web: <http://www.morphosys.de>  
 82152 Planegg E-mail: [info@morphosys.com](mailto:info@morphosys.com)

## Company Profile

MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. Its clinical programs focus on Pelabresib and Tulumimetostat. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	814,021,000		1,089,040,000		1,132,969,000	
<b>Common stock capital</b>		37,655,000		34,231,000		34,231,000
<b>Fixed assets</b>	1,212,289,000		1,307,891,000		1,423,284,000	
<b>Equity capital of a company</b>		49,049,000		157,409,000		244,875,000
<b>Cash and cash equivalents</b>	158,499,000		402,350,000		123,248,000	
<b>Accrued liabilities</b>		28,363,000		8,674,000		1,576,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		264,309,000		278,346,000		284,538,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		1,712,952,000		1,961,176,000		2,026,839,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		1,425,221,000		1,616,129,000		1,681,067,000
<b>Total assets</b>	2,026,311,000	2,026,311,000	2,396,932,000	2,396,932,000	2,556,254,000	2,556,254,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	564	647	732
<b>Equity ratio</b>	2.42%	6.57%	9.58%
<b>Debt-equity ratio</b>	4,031.18%	1,422.74%	943.90%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	0.65%	772.40%	12.96%

**Income statement**

	<b>2023</b>	<b>2022</b>	<b>2021</b>
<b>Turnover</b>	238,278,000	278,267,000	179,611,000
<b>Net income</b>	-189,734,000	-151,058,000	-514,460,000
<b>EBIT</b>	-107,488,845	133,998,322	-525,707,538
<b>Operating income before taxes</b>	-182,748,000	21,825,000	-591,050,000
<b>Cash Flow</b>	-279,448,000	-366,845,000	-484,572,000
<b>Net interest income</b>	-75,259,000	-112,172,000	-65,343,000
<b>Research and development expenses</b>	266,646,000	284,543,000	219,072,000
<b>Income taxes</b>	-1,188,000	168,578,000	-76,590,000
<b>Result from investments in subsidiaries, associates and other</b>	-8,174,000	-4,305,000	0
<b>Revenues per employee</b>	422,479	430,088	245,371

**Board of Directors**

Heinrich Moisa	Member of Supervisory Board
Romain Lege	Member of Supervisory Board
Sharon Curran	Member of Supervisory Board
Silke Mainka	Member of Supervisory Board

**Members of Management Board**

Arkadius Pichota	Chairman of Managing Board
Barbara Krebs-Pohl	Member of Executive Committee
Tim Demuth	Member of Executive Committee
Charlotte Lohmann	Member of Executive Committee
Lukas Gilgen	Member of Executive Committee